Therefore, using CBL in combination with Rova-T may add therapeutic value to disappointing recent results with Rova-T alone in SCLC,12,13 and could represent a novel drug combination that can prevent tumour recurrence and yield a more durable response in this cancer. The gene discussed is CBL; the disease is neoplasm.